Today: 30 April 2026
Agricultural Bank of China Class A shares dip to 6.75 yuan — what to watch before Shanghai reopens
25 January 2026
2 mins read

Agricultural Bank of China Class A shares dip to 6.75 yuan — what to watch before Shanghai reopens

Shanghai, Jan 26, 2026, 00:42 GMT+8 — The market has closed.

  • Agricultural Bank of China Class A shares closed lower on Friday, dragged down by weakness across the banking sector.
  • Traders kick off the week eyeing the yuan and worldwide rate signals, with attention fixed on the Fed.
  • Official PMI figures from China, due later this week, might shift expectations around credit demand and policy moves.

Agricultural Bank of China Ltd’s Class A shares on the Shanghai exchange ended Friday at 6.75 yuan, slipping 0.06 yuan, or 0.88%, as the weekend approached. The stock’s 52-week range stands between 4.92 and 8.68 yuan, per market data.

As one of China’s “big four” banks, the state-owned lender’s A-shares — mainland stocks traded in yuan — frequently react to changing expectations around stimulus measures, loan expansion, and efforts to address risks tied to the property sector.

Global rate expectations have resurfaced this week as investors zero in on Fed Chair Jerome Powell’s remarks, despite broad anticipation that the central bank will hold steady, according to a Reuters Morning Bid report.

The Federal Reserve’s upcoming policy meeting is set for Jan. 27-28, according to its calendar. Moves in the dollar following the decision often impact the yuan, which in turn can influence foreign demand for Chinese financial stocks.

Friday saw Agricultural Bank of China’s shares fluctuate from 6.73 to 6.86 yuan, with roughly 396 million shares changing hands, according to Yahoo Finance.

Lenders took a cautious stance as the CSI Banks Index slipped 0.92%, closing at 7,032.57 on Jan. 23. The sector headed into Monday’s open on the back foot.

Currency shifts might sway sentiment as well. On Friday, China’s central bank pegged the yuan’s daily fixing at 6.9929 per dollar — marking its strongest level in nearly three years and the first time dipping below 7 since May 2023. Traders often see this as a key policy signal.

China’s commerce ministry reported that foreign direct investment hit 747.7 billion yuan in 2025, marking a 9.5% drop from the previous year. The slowdown in incoming investment could heighten hopes for looser financial policies.

Fiscal backing continues to play a role. Last week, China’s state planner announced the issuance of 93.6 billion yuan in ultra-long-term special treasury bonds aimed at funding equipment upgrades in 2026 — a move that could affect credit demand and the flow of bank loans.

Downside risks remain tied to property and asset quality. Chinese rural banks continue to face challenges selling foreclosed properties, even after slashing prices by 20% to 30%. “We’re definitely in the largest non-performing-asset disposal cycle historically,” Gavekal Dragonomics analyst Xiaoxi Zhang told Reuters. Reuters

Investors will turn their attention to a mix of macro data and policy hints. The National Bureau of Statistics of China has scheduled the January purchasing managers’ index (PMI) report for Jan. 31 at 9:30 a.m. This survey-based measure of factory and services activity could influence expectations around loan demand and potential easing moves.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next
Previous Story

Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next

American Express stock slides into earnings week as Fed decision looms — what to watch next
Next Story

American Express stock slides into earnings week as Fed decision looms — what to watch next

Go toTop